SuperworthEnanta Pharmaceuticals EPS ENTA
Diluted earnings per share by quarter and over the last twelve months, from 2011.
- Last 12 months, to Jun 30, 2026
- −$2.41
- Latest quarter, Q3 FY26
- −$0.67
- Fiscal year 2025
- −$3.83
Enanta Pharmaceuticals' earnings per share was −$2.41 over the twelve months to Jun 30, 2026.
In its latest quarter, Q3 FY26, it was −$0.67.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.83 | n/a |
| FY2024 | −$5.48 | n/a |
| FY2023 | −$6.37 | n/a |
| FY2022 | −$5.91 | n/a |
| FY2021 | −$3.91 | n/a |
| FY2020 | −$1.82 | −182% |
| FY2019 | $2.22 | −36% |
| FY2018 | $3.47 | +294% |
| FY2017 | $0.88 | −21% |
| FY2016 | $1.12 | −73% |
| FY2015 | $4.09 | +132% |
| FY2014 | $1.76 | n/a |
| FY2013 | −$1.31 | n/a |
| FY2012 | −$2.73 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.67 | n/a | −$2.41 | |
| Q2 FY26 | −$0.45 | n/a | −$2.59 | |
| Q1 FY26 | −$0.42 | n/a | −$3.20 | |
| Q4 FY25 | −$0.87 | n/a | −$3.83 | |
| Q3 FY25 | −$0.85 | n/a | −$4.32 | |
| Q2 FY25 | −$1.06 | n/a | −$4.54 | |
| Q1 FY25 | −$1.05 | n/a | −$4.95 | |
| Q4 FY24 | −$1.36 | n/a | −$5.48 | |
| Q3 FY24 | −$1.07 | n/a | −$5.45 | |
| Q2 FY24 | −$1.47 | n/a | −$6.24 | |
| Q1 FY24 | −$1.58 | n/a | −$6.56 | |
| Q4 FY23 | −$1.33 | n/a | −$6.37 |
Against its peers
Companies in Drug Manufacturers - General nearest Enanta Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ENTAEnanta Pharmaceuticals | −$2.41 | |
| ARVNArvinas | $0.16 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Enanta Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.